Wilms tumor (WT) is the most common renal malignancy in children. This classic embryonic tumor resembles the fetal kidney in gene expression 1 and morphology. 2 WT consists most often of three tumor cell components, analogous to the condensing metanephric mesenchyme and its derivatives (ie, blastemal, stromal, and epithelial elements). 1 Another rare WT component is anaplasia, consisting of tumor cells with a highly variable nuclear size, nuclear hyperchromasia, and irregular mitotic figures. These features are rarely observed in other WT components and do not resemble any equivalent component in normal kidney development. 3 Currently, the overall survival for WT patients is approaching 90%. 4, 5 Correct histopathologic risk stratification is of great importance for the accurate treatment of patients with WT. WTs were treated as stated by the International Society of Paediatric Oncology-Renal Tumour Study Group (SIOP 2001) protocol, 2 according to which most European patients are managed, and The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit ™ per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
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were subdivided into different risk groups as specified by tumor stage and the histologic appearance in nephrectomy specimens following preoperative chemotherapy. For these postchemotherapy WTs, two high-risk groups are recognized by histology: blastemal WT (more than two-thirds of blastemal cells in the viable tumor component) and diffuse anaplastic WT. Tumors belonging to these high-risk groups sometimes may be difficult to recognize by H&E staining alone. In particular, it can be challenging to distinguish blastemal elements from dense aggregates of epithelial cells with only rudimentary tubule formation. Even though cytokeratin immunohistochemical staining may be helpful in this respect, a positive blastemal marker with high sensitivity and specificity would be useful to increase precision in the quantification of blastema. To our knowledge, no biomarkers are in clinical use for the blastemal component of WT. In the literature, there have been some suggestions of blastemal markers, such as CITED1, 6,7 SIX1, 8 and CD56, 7 primarily based on the expression of these proteins in the human embryonic kidney. However, expression of these markers in WT blastema has been studied only in small sample series, and their potential clinical use has not received much evaluation. CITED1 and SIX1 are both transcription factors 9 expressed in the normal human fetal kidney in the condensing mesenchyme. 6, 10 The SIX gene family includes homologues to the Drosophila sine oculis genes. It is expressed in the cap mesenchyme before initiation of ureteric bud branching during kidney development. 11 Cited1 is also expressed in progenitor cells in the cap mesenchyme cells during nephrogenesis and is downregulated during further mesenchymal to epithelial transition. 12 Mutations in SIX1 have been shown to be one cause of branchiootorenal syndrome, which includes renal dysplasia. 13 Its coordinated expression during embryogenesis is therefore thought to be crucial for normal kidney development. 14 In contrast, deletion of Cited1 does not disrupt normal kidney development, implying some redundancy in its nephrogenic role. 12 CD56, a cell surface protein involved in cell-to-cell adhesion, is active during development and differentiation. 15 In the present study, the protein expression of these three potential biomarkers was evaluated in the three common histologic components (blastema, epithelium, and stroma) of WT as well as in normal renal tissue and other pediatric renal neoplasms, such as clear cell sarcoma (CCSK), adenocarcinoma (ADCA), rhabdoid tumor (RAT), and mesoblastic nephroma (MN).
Materials and Methods

TMA Tissue Sections
This study was approved by the regional ethics committee for southern Sweden (LU119-03). All patients were included after obtaining written informed parental consent.
Tissue sections from pediatric renal tumors, adjacent normal kidney tissue, and fetal kidneys were obtained from the biobank of the Department of Pathology, Lund University, and Regional Laboratories, Lund, Sweden. Cases were selected among patients with renal tumors treated according to the SIOP 2001 or SIOP 93-01 protocols, based on tumor tissue availability for ancillary studies. All cases were reviewed by a local pathologist (D.G.) as well as the SIOP consortium reference pathologist. Tissue microarrays (TMAs) were constructed from paraffin-embedded primary tumor nephrectomy material from 30 WTs ❚Table 1❚, two CCSKs, two RATs, two ADCAs, and one MN, corresponding to 37 patients (one tumor per patient). From the WT postchemotherapy nephrectomy specimens, at least one TMA core was obtained from each blastemal, epithelial, and stromal component when present in initial or diagnostic H&E-stained sections. Material from relapse WTs was also included in the TMA when available (seven patients). In addition, samples from adjacent nontumor renal tissue were available and included from 28 patients with WT. To recover missing or suspected missing WT components not present in the TMA cores that were present in the initial or diagnostic sections, the TMA was complemented by routine sections in 18 of 30 primary WT cases. 
Detection of Protein Expression
To enable concurrent analysis of epithelial and candidate blastemal markers, we performed dual-color immunofluorescence staining. Paraffin sections of 3.5 µm were cut to positively charged slides (DAKO, Glostrup, Denmark), dried, and deparaffinized. A pressure heater (Decloaking Chamber DC2002 CE; BIOCARE, Concord, CA) was used for heatinduced epitope retrieval, performed at 100°C or 120°C for 15 minutes. Slides were blocked with 1% milk powder in phosphate-buffered saline for 30 minutes at room temperature. HPA006299; ATLAS), was used as a marker for epithelial differentiation in the tissue sections. All tested antibodies were evaluated broadly for specificity by comparing cellular staining location with that described in the Human Protein Atlas (http://www.proteinatlas.org/). Protein expression was graded by staining intensity from 0 to 3 and defined as negative (0-1) or positive (2-3). Slides stained in parallel with secondary antibodies only were used as negative controls for relative scoring of protein expression. Blastemal elements were defined as dense clusters of cells that are devoid of spindle cell morphology but have large nuclei, a high nuclear to cytoplasmic ratio, but lack tubular formations or cytokeratin positivity in a pattern suggesting tubule formation.
Results
Sensitivity and Specificity for Blastema in Primary WTs
Using the criteria specified above, CITED1, CD56, and SIX1 were all negative (0-1) in nontumor kidney samples, with CITED1 showing intensity 1 staining of proximal tubules; CD56 demonstrating intensity 1 staining in all components, including the tubule, stroma, and glomeruli; and SIX1 having intensity 0 in all components. Of the 30 primary WTs, 19 contained blastemal, 28 epithelial, and 29 stromal elements in a sufficient amount for protein expression analysis of all three candidate blastemal markers ❚Image 1A❚, ❚Image 1B❚, ❚Image 1C❚, and ❚Image 1D❚. According to the initial H&E staining, six additional WTs appeared to contain minor blastemal components; however, cytokeratin staining performed in the present study showed that these components instead consisted of tubule-forming cytokeratin-positive dense epithelial aggregates ❚Image 1E❚ and ❚Image 1F❚. In two additional cases, analysis of blastema was prevented by extensive necrosis.
❚Image 1❚ Immunofluorescence (A-C, E) and H&E (D, F) staining of primary Wilms tumors (A-D, patient 13; and E-F, patient 9). For the immunofluorescence stainings, the nuclei were counterstained with 4,6-diamidino-2-phenylindole (blue) and the epithelial component stained with cytokeratin (green) (×10). A, CITED1 (red) is expressed in the blastemal (b) and focally (arrow) in epithelial (e) components but not in the stromal (s) component. B, SIX1 (red) is expressed only in the blastemal component and not in the epithelial or stromal component.
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Blastemal Marker Stability Over Time in Patients With WT and Relapse
Five primary WTs with available material from relapses that contained blastema in their primary tumors were also analyzed ❚Figure 3❚. One WT (patient 12) exhibited a totally necrotic primary tumor without any blastema in the tumornephrectomy specimen, but prechemotherapy core needle biopsy material and a relapse sample contained blastemal elements. CITED1, SIX1, and CD56 were all positive (intensity 2-3) or weak (intensity 1) in the blastemal components of primary tumors as well as the relapses, with little shift in expression profile over time.
Blastemal components were positive for CITED1 expression in 100% (19/19), for SIX1 in 89% (17/19), and for CD56 in 74% (14/19) of the primary WTs with viable blastema ❚Figure 1❚ and ❚Figure 2❚. Typically, more than 90% of blastemal cells were stained in cases scored as positive. The stromal components were in most cases (62%) positive for CD56 and less often so for CITED1 and SIX1 (48% and 52% of cases, respectively). Epithelial elements were frequently positive for CITED1 (64%) and CD56 (79%) but not for SIX1 (25%). In the two cases of the diffuse anaplastic subtype (Table 1) , anaplastic elements were CD56 positive in both, CITED1 positive in one, and SIX1 positive in the other.
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❚Image 1❚ (cont) C, CD56 (red) is expressed in the blastemal, epithelial (arrows), and stromal components. D, Routine H&E staining. E, All dense cell aggregates are cytokeratin positive and display epithelial formation to some extent, even in blastemalike areas (arrows). F, Routine H&E staining showing blastemal-like components in the same area (arrows).
Blastemal Marker Expression in Non-WTs
All non-WTs represented on the TMA, including CCSK, RAT, ADCA, and MN, proved to be negative for CITED1, SIX1, and CD56. However, weak staining (intensity 1) was observed for all three markers in some of the cases. SIX1 displayed weak staining in one CCSK and one RAT. 
Discussion
The TMA method has several weak points when examining WTs. In particular, it may be noninclusive since each TMA core represents only a small area of each tumor. Since WTs are triphasic, some informative tissue elements could be excluded by the TMA approach. We tried to avoid this issue by collecting multiple cores from each tumor, with each element covered by at least one core. The advantage of TMA is a fast screening process and consistent result, since stainings of the same part of the tumor are being compared.
None of the tested proteins proved to be an optimal blastemal marker in WT. CITED1 was the most sensitive biomarker for blastema of those tested. However, it also proved to stain the epithelial component of WT to a greater extent than did SIX1. The epithelial component of WT is easier to confuse with blastema than the stromal component, a fact that should not be underestimated. SIX1 was shown to be a more specific blastemal marker but did not stain blastema in all tested WTs. CD56 generally showed low sensitivity and specificity, indicating that it should not be recommended as a blastemal marker in WT, since it stained WT epithelial and stromal components at a higher frequency and blastemal components at a lower frequency than did the other two markers. Expression of the three proteins in postchemotherapy-treated nontumor kidney tissue resembled that in WT, with CITED1 displaying some staining in epithelial components, while CD56 was to some extent expressed in all components and SIX1 in none of the normal kidney elements. In the relapsed WTs, a shift in expression for SIX1 and CITED1 was observed in one patient each, while two patients showed a shift in CD56 status. This argues that at least SIX1 and CITED1 expression remains stable during progression of WT blastema. However, the relapsed patients in this study were fairly low in number. We found no significant difference between patients with different CITED1/SIX1/CD56 staining profiles in primary tumors with regard to relapse risk or survival.
Routine cytokeratin staining appeared to be a greater asset than first assumed, since it revealed components that, according to the H&E staining, appeared blastemal but were shown to consist of dense epithelial aggregates only clearly visible on cytokeratin staining (Image 1E-1F). This indicates that clinical implementation of CITED1 and/or SIX1 detection for recognizing WT blastema would be greatly enhanced by dual-color staining using a broad cytokeratin or similar epithelial marker combined with either CITED1 or SIX1, particularly since they both stained epithelial elements in several cases. In such a context, CITED1 and SIX1 could prove helpful in discriminating dense epithelial aggregates from blastema and quantifying viable blastema in postchemotherapy WTs. Because these markers have different sensitivity and specificity profiles, it could be recommended to use them for screening of WT when striving for a precise estimate of blastema in available material. Furthermore, the application of immunohistochemical blastemal markers could be expected to reduce discrepancies between primary/local pathologists and reference pathologists. Considering that neither CITED1 nor SIX1 was strongly expressed in other, rarer renal childhood tumors, they may also have a role in differential diagnosis. However, a study on a larger panel of non-WTs than that available to us would have to be performed before this issue can be addressed in detail.
❚Figure 3❚ CITED1, SIX1, and CD56 staining of blastema scored as positive (intensity 2-3), weak (intensity 1), and absent in relapsed patients. Annotations are as follows: core needle biopsy (B), primary tumor (P), relapse (R), dead of complications (DOC), dead of disease (DOD), and no evidence of disease (NED). 
